By Paul Reed : The market need for Cologuard Only 0.3% of the population currently suffers from colon cancer, but the lifetime risk is higher at 5%, which benefits the colon cancer screening market. According to the American Cancer Society : "96,830 new cases of colon cancer and 40,000 new cases of
Exact Sciences ( EXAS +5.5% ) offers 10M shares of common stock at $12.75/share to the public. ~$119.7M net proceeds will fund regulatory
came public today. It has a better dividend (than Chambers Street) and better prospects." Bearish Calls: Exact Sciences ( EXAS ): "We liked this stock leading up to the FDA approval. Once you get approval, a stock like this is done
ancillary-benefit suppliers MET, UNM ; PBMs CVS, ESRX ; managed-care providers AET, UNH, CI ; pg 17]; Exact Sciences [ EXAS ; impending FDA approval of its colon cancer screening test; pg 19]; REITs with DC office exposure [ BDN
Gainers: IDRA +18% . ICLD +12% . RH +8% . MNKD +8% . MERC +7% . ARIA +6% . HALO +6% . EXAS +5% . MY +5% . Losers: LPDX -22% . INO -11% . WHX -8% . CZR -8% . MTL -7% . VJET -7% . EXLP -5% . NWBO -5% . Post your comment!
On the basis of yesterday's unanimous ad comm recommendation for regulatory approval of Cologuard, shares of EXACT Sciences ( EXAS ) are poised for an up move this morning. Analysts expect sales to ramp up quickly. Post your comment!
* Mdxhealth licensee exact sciences receives fda panel recommendation for approval of colorectal cancer screening test
Market chatter says today's Ad comm vote on EXACT Science's ( EXAS ) ColoGuard was 10-0 recommending approval. Trading was halted today pending the news but will resume after the close. 1 comment!
Exact Sciences ' ( EXAS ) shares have been halted ahead of a meeting of an FDA committee to discuss the company's premarket approval application for
By Beacon VP Investments: Exact Sciences ( EXAS ) is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting